•  
  •  
  •  
  •  

2025-12-29 06:35:08

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • MOU between IITM Pravartak and Methodhub Software Limited
  • Ola Electric scales up deliveries of 4680 Bharat Cell Powered Vehicles
  • MD and CEO of Sigachi Industries Ltd remanded
  • The Monarch Surveyors and Engineering Consultants Ltd receives order worth Rs. 3.29 crore
  • Kotak Mahindra Bank Ltd fixes Jan 14, 2026 as record date for 5:1 stock split

Keywords Selected:  Biosimilar

Stock Report

  • CuraTeQ Biologics Pvt Ltd and BioFactura Inc, USA to terminate agreement mutually
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients
  • Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
  • Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Lupin announces licensing deal for Ranibizumab Biosimilar
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
  • EMA's CHMP recommends approval of Biocon Biologics' YESINTEK®, biosimilar to J&J's Stelara®

Latest Post

  • MOU between IITM Pravartak and Methodhub Software Limited
  • Ola Electric scales up deliveries of 4680 Bharat Cell Powered Vehicles
  • MD and CEO of Sigachi Industries Ltd remanded
  • The Monarch Surveyors and Engineering Consultants Ltd receives order worth Rs. 3.29 crore
  • Kotak Mahindra Bank Ltd fixes Jan 14, 2026 as record date for 5:1 stock split


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024